CN1427076A - 一种联合缺失19Kda、55KDA E1B编码序列重组腺病毒构建体的构建及用途 - Google Patents
一种联合缺失19Kda、55KDA E1B编码序列重组腺病毒构建体的构建及用途 Download PDFInfo
- Publication number
- CN1427076A CN1427076A CN 01144629 CN01144629A CN1427076A CN 1427076 A CN1427076 A CN 1427076A CN 01144629 CN01144629 CN 01144629 CN 01144629 A CN01144629 A CN 01144629A CN 1427076 A CN1427076 A CN 1427076A
- Authority
- CN
- China
- Prior art keywords
- adenovirus
- adv5
- 55kda
- construction body
- reorganization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 62
- 238000010276 construction Methods 0.000 title claims description 20
- 230000006798 recombination Effects 0.000 title claims description 18
- 238000005215 recombination Methods 0.000 title claims description 18
- 238000012217 deletion Methods 0.000 title description 2
- 230000037430 deletion Effects 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- 108090000790 Enzymes Proteins 0.000 claims abstract description 8
- 102000004190 Enzymes Human genes 0.000 claims abstract description 8
- 238000005516 engineering process Methods 0.000 claims abstract description 6
- 238000012408 PCR amplification Methods 0.000 claims abstract description 4
- 238000000746 purification Methods 0.000 claims abstract 2
- 230000008034 disappearance Effects 0.000 claims description 17
- 230000008521 reorganization Effects 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 108091026890 Coding region Proteins 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 238000001415 gene therapy Methods 0.000 claims description 9
- 238000004806 packaging method and process Methods 0.000 claims description 9
- 239000013612 plasmid Substances 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108010033040 Histones Proteins 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 29
- 210000004881 tumor cell Anatomy 0.000 abstract description 17
- 238000001890 transfection Methods 0.000 abstract description 5
- 241001135569 Human adenovirus 5 Species 0.000 abstract description 3
- 238000010367 cloning Methods 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 description 19
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 13
- 230000022534 cell killing Effects 0.000 description 11
- 108700025694 p53 Genes Proteins 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 230000002950 deficient Effects 0.000 description 7
- 230000002147 killing effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000005336 cracking Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000002424 anti-apoptotic effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000004179 Oral Leukoplakia Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 201000008557 oral mucosa leukoplakia Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000026487 Triploidy Diseases 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 101150010855 cma gene Proteins 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
野生型人腺腺病毒5 | 重组E1B全缺失腺病毒 | 重组E1、E3缺失腺病毒 | |
U-2OS细胞杀伤率 | |||
第四天 | 50% | 1% | 1% |
第八天 | 100% | 2% | 2% |
第十二天 | 4% | 4% | |
HS700T细胞杀伤率 |
第四天 | 70% | 10% | 1% |
第八天 | 100% | 25% | 2% |
第十二天 | 90% | 3% | |
DLD-1细胞杀伤率 | |||
第四天 | 50% | 10% | 1% |
第八天 | 100% | 25% | 2% |
第十二天 | 90% | 4% | |
IMR90细胞杀伤率 | |||
第四天 | 50% | 1% | 1% |
第八天 | 100% | 2% | 2% |
第十二天 | 3% | 1% | |
293细胞杀伤率 | |||
第四天 | 50% | 50% | 50% |
第八天 | 100% | 100% | 100% |
第十二天 |
野生型人腺病毒5- + | 重组E1B全缺失腺病毒- + | 重组E1、E3缺失腺病毒- + | |
U-2OS细胞杀伤率 | 顺铂 (0.2μg/ml) | 顺铂 (0.2μg/ml) | 顺铂 (0.2μg/ml) |
第四天 | 25% 90% | 25% 30% | 25% 30% |
HS700T细胞杀伤率 | 顺铂 (0.2μg/ml) | 顺铂 (0.2μg/ml) | 顺铂 (0.2μg/ml) |
第四天 | 15% 95% | 15% 95% | 15% 25% |
DLD-1细胞杀伤率 | 顺铂 (0.2μg/ml) | 顺铂 (0.2μg/ml) | 顺铂 (0.2μg/ml) |
第四天 | 18% 92% | 18% 96% | 18% 25% |
IMR90细胞杀伤率 | 顺铂 (0.2μg/ml) | 顺铂 (0.2μg/ml) | 顺铂 (0.2μg/ml) |
第四天 | 5% 80% | 5% 8% | 5% 6% |
293细胞杀伤率 | 顺铂 (0.2μg/ml) | 顺铂 (0.2μg/ml) | 顺铂 (0.2μg/ml) |
第四天 | 15% 95% | 15% 93% | 15% 95% |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011446293A CN1184310C (zh) | 2001-12-21 | 2001-12-21 | 一种联合缺失19Kda、55KDA E1B编码序列重组腺病毒构建体的构建及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011446293A CN1184310C (zh) | 2001-12-21 | 2001-12-21 | 一种联合缺失19Kda、55KDA E1B编码序列重组腺病毒构建体的构建及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1427076A true CN1427076A (zh) | 2003-07-02 |
CN1184310C CN1184310C (zh) | 2005-01-12 |
Family
ID=4677722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB011446293A Expired - Lifetime CN1184310C (zh) | 2001-12-21 | 2001-12-21 | 一种联合缺失19Kda、55KDA E1B编码序列重组腺病毒构建体的构建及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1184310C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102220292A (zh) * | 2010-04-15 | 2011-10-19 | 中国医学科学院肿瘤研究所 | 重组ⅱ型单纯疱疹病毒、其制备方法及应用和肿瘤诊断试剂盒 |
CN102399777A (zh) * | 2011-10-21 | 2012-04-04 | 中国人民解放军军事医学科学院生物工程研究所 | 一种重组质粒及应用其制备的重组溶瘤腺病毒 |
CN113677370A (zh) * | 2018-12-20 | 2021-11-19 | 马德里自治大学 | 使用细小病毒治疗携带TP53基因突变和/或p53蛋白翻译后修饰的癌症 |
-
2001
- 2001-12-21 CN CNB011446293A patent/CN1184310C/zh not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102220292A (zh) * | 2010-04-15 | 2011-10-19 | 中国医学科学院肿瘤研究所 | 重组ⅱ型单纯疱疹病毒、其制备方法及应用和肿瘤诊断试剂盒 |
CN102399777A (zh) * | 2011-10-21 | 2012-04-04 | 中国人民解放军军事医学科学院生物工程研究所 | 一种重组质粒及应用其制备的重组溶瘤腺病毒 |
CN102399777B (zh) * | 2011-10-21 | 2013-05-15 | 中国人民解放军军事医学科学院生物工程研究所 | 一种重组质粒及应用其制备的重组溶瘤腺病毒 |
CN113677370A (zh) * | 2018-12-20 | 2021-11-19 | 马德里自治大学 | 使用细小病毒治疗携带TP53基因突变和/或p53蛋白翻译后修饰的癌症 |
Also Published As
Publication number | Publication date |
---|---|
CN1184310C (zh) | 2005-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104263703B (zh) | 用于治疗癌症的嵌合腺病毒 | |
CN100390292C (zh) | 甲胎蛋白表达细胞的腺病毒载体及其使用方法 | |
CN102548584A (zh) | 用于治疗癌症的溶瘤腺病毒 | |
DE69726759T2 (de) | Cytopatische viren zur therapie und prophylaxe der neoplasie | |
US20080292592A1 (en) | Oncolytic Adenovirus Armed with Therapeutic Genes | |
HUE026386T2 (en) | Tumor-selective adenovirus E1A and E1B mutants | |
Brücher et al. | iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy | |
JP2014509197A (ja) | 標的性治療人腫瘍治療の腫瘍溶解性アデノウイルス及びその応用 | |
CN105755043B (zh) | 一种双拷贝人p53基因重组腺病毒及其制备方法 | |
ZA200500047B (en) | Tumor-lysing virus growing selectively in tumor cells | |
CN100475966C (zh) | 具有肿瘤细胞特异性感染和转基因表达能力的新型腺病毒 | |
CN101921769A (zh) | 一种重组腺病毒及其制备方法和应用 | |
CN1184310C (zh) | 一种联合缺失19Kda、55KDA E1B编码序列重组腺病毒构建体的构建及用途 | |
CN1169949C (zh) | 一种缺失e1a编码序列的重组腺病毒构建体的获得及用途 | |
CN1952160B (zh) | 智能腺病毒载体与khp53基因的重组体及其应用 | |
EP1662004B1 (en) | Method of preparing a proliferation-regulated recombinant adenoviral vector, kit and vector | |
CN100415298C (zh) | 用于原发性肝癌基因治疗的腺病毒载体及使用方法 | |
CN109554395A (zh) | 一种选择性杀灭***癌细胞的新型溶瘤病毒及其构建方法 | |
CN1393559A (zh) | 肝癌细胞特异的基因工程腺病毒的构建及应用 | |
TWI320056B (en) | Virus clearance of neoplastic cells from mixed cellular compositions | |
CN108424932A (zh) | 重组溶瘤腺病毒、用于制备该重组溶瘤腺病毒的重组溶瘤腺病毒载体及其构建方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN TIANDAKANG GENE ENGINEERING CO., LTD Free format text: FORMER OWNER: ZHOU JIANFENG Effective date: 20030604 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20030604 Applicant after: Shenzhen Tiandakang Genetic Engineering Co.,Ltd. Applicant before: Zhou Jianfeng |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term |
Granted publication date: 20050112 |
|
CX01 | Expiry of patent term | ||
DD01 | Delivery of document by public notice |
Addressee: Shenzhen Tiandakang Genetic Engineering Co.,Ltd. Document name: Notice of expiration and termination of patent right |
|
DD01 | Delivery of document by public notice |